USPTO grants Azitra patent for future potential pipeline candidates for AD

Azitra announced that the U.S. Patent and Trademark Office or USPTO has granted U.S. patent No. 12,036,248, covering future potential pipeline candidates for indications including atopic dermatitis, titled “Therapeutic treatment of skin disease with recombinant skin microorganisms.” The Company also announced three additional newly allowed patents in three countries, including the U.S., Canada, and China: Methods and Compositions for Treating Inflammatory Skin Disease with Recombinant Microorganisms U.S. Patent Application No. 16/121,903… Covers the composition of filaggrin-secreting strains of Staphylococcus epidermidis Methods and Compositions for Treating Atopic Dermatitis with Recombinant Microorganisms Canadian Patent Application No. 3067364 Covers the use of filaggrin-secreting strains of Staphylococcus epidermidis for atopic dermatitis and other skin diseases… Methods and Compositions for Treating Inflammatory Skin Disease with Recombinant Microorganisms Chinese Patent Application No. 201880071303.9 Covers the composition of filaggrin-secreting strains of Staphylococcus epidermidis..Travis Whitfill, Azitra’s COO, co-founder, and inventor of the patents stated, “We are delighted to announce our second US patent issuance this year and three additional patent allowances in key markets in the U.S., Canada, and China. The indication addressed by the newly issued U.S. patent, atopic dermatitis, affects approximately 16.5 million people in the United States. There are numerous diseases associated with filaggrin deficiency, and the newly issued U.S. patent extends our protection to include a major market in the U.S., atopic dermatitis, particularly those with mild to moderate disease. Additionally, the new patent allowances in China and Canada extend our IP strength globally.”